Previous close | 143.26 |
Open | 143.99 |
Bid | 143.71 x 800 |
Ask | 143.90 x 1300 |
Day's range | 138.22 - 144.89 |
52-week range | 115.61 - 497.49 |
Volume | |
Avg. volume | 6,101,277 |
Market cap | 57.385B |
Beta (5Y monthly) | 1.69 |
PE ratio (TTM) | 4.24 |
EPS (TTM) | 34.02 |
Earnings date | 03 Aug 2022 - 08 Aug 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 219.33 |
The FDA approves expanded use of AbbVie's (ABBV) Skyrizi, Merck's (MRK) Vaxneuvance vaccine and Novartis's (NVS) cancer combination drugs, Tafinlar (dabrafenib) + Mekinist (trametinib).
Yahoo Finance's Rachelle Akuffo looks at Moderna's stock following a CDC panel's endorsement of its latest vaccine.
Moderna's (MRNA) bivalent COVID booster candidate exhibits a greater than a 5-fold boost in antibody responses against the Omicron subvariants BA.4 and BA.5 in a phase II/III study.